Literature DB >> 21037434

Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?

Alberto Ruol1, Christian Rizzetto, Carlo Castoro, Matteo Cagol, Rita Alfieri, Gianpietro Zanchettin, Francesco Cavallin, Silvia Michieletto, Gianfranco Da Dalt, Vanna Chiarion Sileni, Luigi Corti, Silvia Mantoan, Giovanni Zaninotto, Ermanno Ancona.   

Abstract

OBJECTIVE: Aim of this study was to evaluate whether delayed surgery after neoadjuvant chemoradiotherapy (CRT) affects postoperative outcomes in patients with locally advanced squamous cell carcinoma (SCC) of the thoracic esophagus.
BACKGROUND: Esophagectomy is usually recommended within 4 to 6 weeks after completion of neoadjuvant CRT. However, the optimal timing of surgery is not clearly defined.
METHODS: A total of 129 consecutive patients with locally advanced esophageal cancer, treated between 1998 and 2007, were retrospectively analyzed using prospectively collected data. Patients were divided into 3 groups on the basis of timing to surgery: group 1, ≤30 days (n = 17); group 2, 31 to 60 days (n = 83); and group 3, 61 to 90 days (n = 29). Subsequently, only 2-numerically more consistent-groups were studied, using the median value of timing intervals as a cutoff level: group A, ≤46 days (n = 66); and group B, >46 days (n = 63).
RESULTS: Groups were comparable in terms of patient and tumor characteristics, type of neoadjuvant regimen, toxicity, postoperative morbidity and mortality rates, tumor downstaging, and pathologic complete responses. The overall 5-year actuarial survival rate was 0% in group 1, 43.1% in group 2, and 35.9% in group 3 (P = 0.13). After R0 resection (n = 106), the 5-year actuarial survival rate was 0%, 51%, and 47.3%, respectively (P = 0.18). Tumor recurrence after R0 resection seemed to be inversely related, even if not significantly (P = 0.17), to the time interval between chemoradiation and surgery: 50% in group 1, 40.6% in group 2, and 21.7% in group 3. When considering only 2 groups, the overall 5-year survival was 33.1% in group A and 42.7% in group B (P = 0.64); after R0 resection, the 5-year survival was 37.8% and 56.3%, respectively (P = 0.18). The rate of tumor recurrence was significantly lower in group B (25%) than in group A (48.3%) (P = 0.02).
CONCLUSION: Delayed surgery after neoadjuvant chemoradiation does not compromise the outcomes of patients with locally advanced SCC of the esophagus. Delaying surgery up to 90 days offers relevant advantages in the clinical management of the patients, can reduce tumor recurrences, and may improve prognosis after complete R0 resection surgery.

Entities:  

Mesh:

Year:  2010        PMID: 21037434     DOI: 10.1097/SLA.0b013e3181fc7f86

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  20 in total

Review 1.  [Squamous cell carcinoma of the esophagus].

Authors:  K Ott; L Sisic; M Büchler
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

2.  [Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].

Authors:  A-K Müller; C Lenschow; D Palmes; N Senninger; R Hummel; K Lindner
Journal:  Chirurg       Date:  2015-09       Impact factor: 0.955

Review 3.  How does genome sequencing impact surgery?

Authors:  Marlies S Reimers; Charla C Engels; Peter J K Kuppen; Cornelis J H van de Velde; Gerrit J Liefers
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

4.  Surgery: Delays may improve outcomes.

Authors:  Rebecca Kirk
Journal:  Nat Rev Clin Oncol       Date:  2011-02       Impact factor: 66.675

Review 5.  Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management.

Authors:  Masahiko Ikebe; Masaru Morita; Manabu Yamamoto; Yasushi Toh
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-05-10

6.  Postoperative complications do not affect long-term outcome in esophageal cancer patients.

Authors:  Kirsten Lindner; Mathias Fritz; Christina Haane; Norbert Senninger; Daniel Palmes; Richard Hummel
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

Review 7.  Multimodal treatment of esophageal cancer.

Authors:  Florian Lordick; Arnulf H Hölscher; Karen Haustermans; Christian Wittekind
Journal:  Langenbecks Arch Surg       Date:  2012-09-13       Impact factor: 3.445

8.  Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action.

Authors:  Yaping Xu; Liming Sheng; Weimin Mao
Journal:  Oncol Lett       Date:  2012-10-24       Impact factor: 2.967

9.  Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics.

Authors:  Hao Zhang; Shan Tan; Wengen Chen; Seth Kligerman; Grace Kim; Warren D D'Souza; Mohan Suntharalingam; Wei Lu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-11-01       Impact factor: 7.038

10.  Complete pathologic response is independent of the timing of esophagectomy following neoadjuvant chemoradiation for esophageal cancer.

Authors:  Smit Singla; Emmanuel Gabriel; Raed Alnaji; William Du; Kristopher Attwood; Hector Nava; Steven N Hochwald; Moshim Kukar
Journal:  J Gastrointest Oncol       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.